A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

Cell

Volumn 167, Issue 1, 2016, Pages 260-274.e22

  Bruna, Alejandra ^a   Rueda, Oscar M ^a   Greenwood, Wendy ^a   Batra, Ankita Sati ^a   Callari, Maurizio ^a   Batra, Rajbir Nath ^a   Pogrebniak, Katherine ^a   Sandoval, Jose ^a   Cassidy, John W ^a   Tufegdzic Vidakovic, Ana ^a   Sammut, Stephen John ^a   Jones, Linda ^a,b   Provenzano, Elena ^b   Baird, Richard ^a,b   Eirew, Peter ^c   Hadfield, James ^a   Eldridge, Matthew ^a   McLaren Douglas, Anne ^d   Barthorpe, Andrew ^d   Lightfoot, Howard ^d   O'Connor, Mark J ^e   Gray, Joe ^f   Cortes, Javier ^g   Baselga, Jose ^h   Marangoni, Elisabetta ⁱ   Welm, Alana L ^j   Aparicio, Samuel ^c   Serra, Violeta ^g   Garnett, Mathew J ^d   Caldas, Carlos ^a,b   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ INSTITUT CURIE   (France)

^j UNIVERSITY OF UTAH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; 4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; ALPELISIB; ANTINEOPLASTIC AGENT; AZD 8055; BUPARLISIB; CISPLATIN; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 8; DACTOLISIB; GEFITINIB; OBATOCLAX; OLAPARIB; PACLITAXEL; PICTILISIB; PROTEIN KINASE B INHIBITOR; PROTEIN P53; RIBOCICLIB; RIDAFOROLIMUS; TALAZOPARIB; TAMOXIFEN; TANESPIMYCIN; TASELISIB; TRANSCRIPTION FACTOR GATA 3; UVOMORULIN; PHARMACOLOGICAL BIOMARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOBANK; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL HETEROGENEITY; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SCREENING; EX VIVO STUDY; EXPLANT; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PATIENT DERIVED TUMOR XENOGRAFT; PHARMACOGENOMICS; PRIORITY JOURNAL; SHORT TERM SURVIVAL; TISSUE PRESERVATION; TREATMENT RESPONSE; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENETICS; PATHOLOGY; PHARMACOGENETIC TESTING;

ANIMALS; BIOLOGICAL SPECIMEN BANKS; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; PHARMACOGENOMIC TESTING; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84988664167     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.08.041     Document Type: Article

References (84)

1. Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Durbin, R.M., Handsaker, R.E., Kang, H.M., Marth, G.T., McVean, G.A., 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature 491 (2012), 56–65.
2. Adzhubei, I., Jordan, D.M., Sunyaev, S.R., Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet., Chapter 7, 2013 Unit7.20.
3. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.L., et al. Australian Pancreatic Cancer Genome Initiative ICGC Breast Cancer Consortium ICGC MMML-Seq Consortium, ICGC PedBrain. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
4. Ali, H.R., Rueda, O.M., Chin, S.F., Curtis, C., Dunning, M.J., Aparicio, S.A., Caldas, C., Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biol., 15, 2014, 431.
5. Aparicio, S., Caldas, C., The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 368 (2013), 842–851.
6. Aparicio, S., Hidalgo, M., Kung, A.L., Examining the utility of patient-derived xenograft mouse models. Nat. Rev. Cancer 15 (2015), 311–316.
7. Bailey, J.A., Gu, Z., Clark, R.A., Reinert, K., Samonte, R.V., Schwartz, S., Adams, M.D., Myers, E.W., Li, P.W., Eichler, E.E., Recent segmental duplications in the human genome. Science 297 (2002), 1003–1007.
8. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehár, J., Kryukov, G.V., Sonkin, D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 (2012), 603–607.
9. Bliss, C.I., The toxicity of poisons applied jointly. Ann. Appl. Biol. 26 (1939), 585–615.
10. Boersma, V., Moatti, N., Segura-Bayona, S., Peuscher, M.H., van der Torre, J., Wevers, B.A., Orthwein, A., Durocher, D., Jacobs, J.J., MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′ end resection. Nature 521 (2015), 537–540.
11. Bouwman, P., Aly, A., Escandell, J.M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17 (2010), 688–695.
12. Bunting, S.F., Callén, E., Wong, N., Chen, H.T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141 (2010), 243–254.
13. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490 (2012), 61–70.
14. Cassidy, J.W., Caldas, C., Bruna, A., Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res. 75 (2015), 2963–2968.
15. Chapman, J.R., Sossick, A.J., Boulton, S.J., Jackson, S.P., BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair. J. Cell Sci. 125 (2012), 3529–3534.
16. Crystal, A.S., Shaw, A.T., Sequist, L.V., Friboulet, L., Niederst, M.J., Lockerman, E.L., Frias, R.L., Gainor, J.F., Amzallag, A., Greninger, P., et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346 (2014), 1480–1486.
17. Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., et al., METABRIC Group. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486 (2012), 346–352.
18. Dawson, S.J., Rueda, O.M., Aparicio, S., Caldas, C., A new genome-driven integrated classification of breast cancer and its implications. EMBO J. 32 (2013), 617–628.
19. DePristo, M.A., Banks, E., Poplin, R., Garimella, K.V., Maguire, J.R., Hartl, C., Philippakis, A.A., del Angel, G., Rivas, M.A., Hanna, M., et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43 (2011), 491–498.
20. DeRose, Y.S., Wang, G., Lin, Y.C., Bernard, P.S., Buys, S.S., Ebbert, M.T., Factor, R., Matsen, C., Milash, B.A., Nelson, E., et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17 (2011), 1514–1520.
21. Ding, L., Ellis, M.J., Li, S., Larson, D.E., Chen, K., Wallis, J.W., Harris, C.C., McLellan, M.D., Fulton, R.S., Fulton, L.L., et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464 (2010), 999–1005.
22. Dong, C., Wei, P., Jian, X., Gibbs, R., Boerwinkle, E., Wang, K., Liu, X., Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum. Mol. Genet. 24 (2015), 2125–2137.
23. Drew, Y., Mulligan, E.A., Vong, W.T., Thomas, H.D., Kahn, S., Kyle, S., Mukhopadhyay, A., Los, G., Hostomsky, Z., Plummer, E.R., et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J. Natl. Cancer Inst. 103 (2011), 334–346.
24. Dunning, M.J., Smith, M.L., Ritchie, M.E., Tavaré, S., beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23 (2007), 2183–2184.
25. Dvinge, H., Git, A., Gräf, S., Salmon-Divon, M., Curtis, C., Sottoriva, A., Zhao, Y., Hirst, M., Armisen, J., Miska, E.A., et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497 (2013), 378–382.
26. Eirew, P., Steif, A., Khattra, J., Ha, G., Yap, D., Farahani, H., Gelmon, K., Chia, S., Mar, C., Wan, A., et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518 (2015), 422–426.
27. Fraley, C., Raftery, A.E., Model-based clustering, discriminant analysis, and density estimation. J. Am. Stat. Assoc. 97 (2002), 611–631.
28. Gao, H., Korn, J.M., Ferretti, S., Monahan, J.E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21 (2015), 1318–1325.
29. Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, C.D., Dastur, A., Lau, K.W., Greninger, P., Thompson, I.R., Luo, X., Soares, J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483 (2012), 570–575.
30. Greco, W.R., Bravo, G., Parsons, J.C., The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47 (1995), 331–385.
31. Hafner, M., Niepel, M., Chung, M., Sorger, P.K., Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13 (2016), 521–527.
32. Haibe-Kains, B., Desmedt, C., Loi, S., Culhane, A.C., Bontempi, G., Quackenbush, J., Sotiriou, C., A three-gene model to robustly identify breast cancer molecular subtypes. J. Natl. Cancer Inst. 104 (2012), 311–325.
33. Hänzelmann, S., Castelo, R., Guinney, J., GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics, 14, 2013, 7.
34. Haverty, P.M., Lin, E., Tan, J., Yu, Y., Lam, B., Lianoglou, S., Neve, R.M., Martin, S., Settleman, J., Yauch, R.L., Bourgon, R., Reproducible pharmacogenomic profiling of cancer cell line panels. Nature 533 (2016), 333–337.
35. Heiser, L.M., Sadanandam, A., Kuo, W.L., Benz, S.C., Goldstein, T.C., Ng, S., Gibb, W.J., Wang, N.J., Ziyad, S., Tong, F., et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl. Acad. Sci. USA 109 (2012), 2724–2729.
36. Heppner, G.H., Tumor heterogeneity. Cancer Res. 44 (1984), 2259–2265.
37. Hidalgo, M., Amant, F., Biankin, A.V., Budinská, E., Byrne, A.T., Caldas, C., Clarke, R.B., de Jong, S., Jonkers, J., Mælandsmo, G.M., et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4 (2014), 998–1013.
38. Huber, W., Carey, V.J., Gentleman, R., Anders, S., Carlson, M., Carvalho, B.S., Bravo, H.C., Davis, S., Gatto, L., Girke, T., et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat. Methods 12 (2015), 115–121.
39. Jurasinski, G., Koebsch, F., Guenther, A., and Beetz, S. (2014). flux: Flux rate calculation from dynamic closed chamber measurements.
40. Kaelin, W.G. Jr., The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5 (2005), 689–698.
41. Kim, H.S., Sung, Y.J., Paik, S., Cancer cell line panels empower genomics-based discovery of precision cancer medicine. Yonsei Med. J. 56 (2015), 1186–1198.
42. Krueger, F., Andrews, S.R., Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27 (2011), 1571–1572.
43. Kuilman, T., Velds, A., Kemper, K., Ranzani, M., Bombardelli, L., Hoogstraat, M., Nevedomskaya, E., Xu, G., de Ruiter, J., Lolkema, M.P., et al. CopywriteR: DNA copy number detection from off-target sequence data. Genome Biol., 16, 2015, 49.
44. Kumar, P., Henikoff, S., Ng, P.C., Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4 (2009), 1073–1081.
45. Lawson, D.A., Bhakta, N.R., Kessenbrock, K., Prummel, K.D., Yu, Y., Takai, K., Zhou, A., Eyob, H., Balakrishnan, S., Wang, C.Y., et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 526 (2015), 131–135.
46. Li, H., Durbin, R., Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25 (2009), 1754–1760.
47. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25 (2009), 2078–2079.
48. Li, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 4 (2013), 1116–1130.
49. Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., Mesirov, J.P., Molecular signatures database (MSigDB) 3.0. Bioinformatics 27 (2011), 1739–1740.
50. Luo, J., Solimini, N.L., Elledge, S.J., Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136 (2009), 823–837.
51. Marangoni, E., Poupon, M.F., Patient-derived tumour xenografts as models for breast cancer drug development. Curr. Opin. Oncol. 26 (2014), 556–561.
52. Marangoni, E., Vincent-Salomon, A., Auger, N., Degeorges, A., Assayag, F., de Cremoux, P., de Plater, L., Guyader, C., De Pinieux, G., Judde, J.G., et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin. Cancer Res. 13 (2007), 3989–3998.
53. Marcotte, R., Sayad, A., Brown, K.R., Sanchez-Garcia, F., Reimand, J., Haider, M., Virtanen, C., Bradner, J.E., Bader, G.D., Mills, G.B., et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell 164 (2016), 293–309.
54. Messersmith, W.A., Rajeshkumar, N.V., Tan, A.C., Wang, X.F., Diesl, V., Choe, S.E., Follettie, M., Coughlin, C., Boschelli, F., Garcia-Garcia, E., et al. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol. Cancer Ther. 8 (2009), 1484–1493.
55. Meyer, M.C., Wu, J., and Opsomer, J.D. (2014). isotonic.pen: Penalized Isotonic Regression in one and two dimensions.
56. Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., D'Andrea, G., Dickler, M., Moynahan, M.E., Sugarman, S., et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 17 (2011), 5132–5139.
57. Mroz, E.A., Rocco, J.W., MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol. 49 (2013), 211–215.
58. Murtaza, M., Dawson, S.J., Pogrebniak, K., Rueda, O.M., Provenzano, E., Grant, J., Chin, S.F., Tsui, D.W., Marass, F., Gale, D., et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat. Commun., 6, 2015, 8760.
59. Obenchain, V., Lawrence, M., Carey, V., Gogarten, S., Shannon, P., Morgan, M., VariantAnnotation: a Bioconductor package for exploration and annotation of genetic variants. Bioinformatics 30 (2014), 2076–2078.
60. Olshen, A.B., Venkatraman, E.S., Lucito, R., Wigler, M., Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5 (2004), 557–572.
61. Parker, J.S., Mullins, M., Cheang, M.C.U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27 (2009), 1160–1167.
62. Pereira, B., Chin, S.F., Rueda, O.M., Vollan, H.K., Provenzano, E., Bardwell, H.A., Pugh, M., Jones, L., Russell, R., Sammut, S.J., et al. Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nat. Commun., 7, 2016, 11908.
63. R Core Team (2016). R: A language and environment for statistical computing.
64. Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B.S., Swanton, C., DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol., 17, 2016, 31.
65. Roth, A., Khattra, J., Yap, D., Wan, A., Laks, E., Biele, J., Ha, G., Aparicio, S., Bouchard-Côté, A., Shah, S.P., PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11 (2014), 396–398.
66. Scheinin, I., Sie, D., Bengtsson, H., van de Wiel, M.A., Olshen, A.B., van Thuijl, H.F., van Essen, H.F., Eijk, P.P., Rustenburg, F., Meijer, G.A., et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res. 24 (2014), 2022–2032.
67. Schwarz, J.M., Rödelsperger, C., Schuelke, M., Seelow, D., MutationTaster evaluates disease-causing potential of sequence alterations. Nat. Methods 7 (2010), 575–576.
68. Shah, S.P., Morin, R.D., Khattra, J., Prentice, L., Pugh, T., Burleigh, A., Delaney, A., Gelmon, K., Guliany, R., Senz, J., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461 (2009), 809–813.
69. Shah, S.P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486 (2012), 395–399.
70. Shalem, O., Sanjana, N.E., Zhang, F., High-throughput functional genomics using CRISPR-Cas9. Nat. Rev. Genet. 16 (2015), 299–311.
71. Sharma, S.V., Haber, D.A., Settleman, J., Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer 10 (2010), 241–253.
72. Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M., Sirotkin, K., dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29 (2001), 308–311.
73. Shu, S., Lin, C.Y., He, H.H., Witwicki, R.M., Tabassum, D.P., Roberts, J.M., Janiszewska, M., Huh, S.J., Liang, Y., Ryan, J., et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 529 (2016), 413–417.
74. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
75. Tabassum, D.P., Polyak, K., Tumorigenesis: it takes a village. Nat. Rev. Cancer 15 (2015), 473–483.
76. Tamayo, P., Cho, Y.-J., Tsherniak, A., Greulich, H., Ambrogio, L., Schouten-van Meeteren, N., Zhou, T., Buxton, A., Kool, M., Meyerson, M., et al. Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J. Clin. Oncol. 29 (2011), 1415–1423.
77. Tentler, J.J., Tan, A.C., Weekes, C.D., Jimeno, A., Leong, S., Pitts, T.M., Arcaroli, J.J., Messersmith, W.A., Eckhardt, S.G., Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9 (2012), 338–350.
78. Torti, D., Trusolino, L., Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol. Med. 3 (2011), 623–636.
79. van de Wetering, M., Francies, H.E., Francis, J.M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161 (2015), 933–945.
80. Van Loo, P., Nordgard, S.H., Lingjærde, O.C., Russnes, H.G., Rye, I.H., Sun, W., Weigman, V.J., Marynen, P., Zetterberg, A., Naume, B., et al. Allele-specific copy number analysis of tumors. Proc. Natl. Acad. Sci. USA 107 (2010), 16910–16915.
81. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr., Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
82. Wang, K., Li, M., Hakonarson, H., ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res., 38, 2010, e164.
83. Wood, S.N., Stable and efficient multiple smoothing parameter estimation for generalized additive models. J. Am. Stat. Assoc. 99 (2004), 673–686.
84. Xu, G., Chapman, J.R., Brandsma, I., Yuan, J., Mistrik, M., Bouwman, P., Bartkova, J., Gogola, E., Warmerdam, D., Barazas, M., et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature 521 (2015), 541–544.